Evidence map›Paper›PMID 39521313›Full record

ArticleActa biomaterialia2025

Targeted CRISPR regulation of ZNF865 enhances stem cell cartilage deposition, tissue maturation rates, and mechanical properties in engineered intervertebral discs.

Hunter Levis, Christian Lewis, Matthew Fainor, Ameerah Lawal, Elise Stockham, Jacob Weston, Niloofar Farhang, Sarah E Gullbrand, Robby D Bowles

Abstract read
In one paragraph

Article in Acta biomaterialia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Harnessing CRISPR potential for intervertebral disc regeneration strategies.Frontiers in bioengineering and biotechnology · 2025
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hunter LevisDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States.
Christian LewisDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States.
Matthew FainorDepartment of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, United States; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States.
Ameerah LawalDepartment of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, United States; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States.
Elise StockhamDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States.
Jacob WestonDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States.
Niloofar FarhangDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States.
Sarah E GullbrandDepartment of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, United States; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States.
Robby D BowlesDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States; Department of Orthopaedic Surgery, University of Utah, Salt Lake City, UT, United States. Electronic address: Robert.Bowles@utah.edu.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Sequence-specific CRISPR mediated inflammatory cytokine receptor modulation for the treatment of inflammatory intervertebral disc pathologyR01AR074998 · NIAMS · UNIVERSITY OF UTAH · PI BOWLES, ROBERT D. · 2019 to 2023
$1.7M
Novel Zinc-Finger Protein Regulator of Senescence and Cell EngineeringR01AR083990 · NIAMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Robert D. Bowles · 2024 to 2026
$1.2M
Amnis ImageStreamX MarkII Imaging Flow CytometerS10OD026959 · OD · UNIVERSITY OF UTAH · PI MARVIN, JAMES E · 2020 to 2020
$517k
NCI NIH HHS P30 CA042014NIAMS NIH HHS R01 AR074998NIAMS NIH HHS R01 AR083990NIH HHS S10 OD026959
6 · The paper itself

Abstract

Cell and tissue engineering based approaches have garnered significant interest for treating intervertebral disc degeneration and associated low back pain due to the substantial limitations of currently available clinical treatments. Herein we present a clustered regularly interspaced short palindromic repeats (CRISPR)-guided gene modulation strategy to improve the therapeutic potential of cell and tissue engineering therapies for treating intervertebral disc disease. Recently, we discovered a zinc finger (ZNF) protein, ZNF865 (BLST), which is associated with no in-depth publications and has not been functionally characterized. Utilizing CRISPR-guided gene modulation, we show that ZNF865 regulates cell cycle progression and protein processing. As a result, regulating this gene acts as a primary titratable regulator of cell activity. We also demonstrate that targeted ZNF865 regulation can enhance protein production and fibrocartilage-like matrix deposition in human adipose-derived stem cells (hASCs). Furthermore, we demonstrate CRISPR-engineered hASCs ability to increase GAG and collagen II matrix deposition in human-size tissue-engineered discs by 8.5-fold and 88.6-fold, respectively, while not increasing collagen X expression compared to naive hASCs dosed with growth factors. With this increased tissue deposition, we observe significant improvements in compressive mechanical properties, generating a stiffer and more robust tissue. Overall, we present novel biology on ZNF865 and display the power of CRISPR-cell engineering to enhance strategies treating musculoskeletal disease. STATEMENT OF SIGNIFICANCE: This work reports on a novel gene, ZNF865 (also known as BLST), that when regulated with CRISPRa, improves cartilagenous tissue deposition in human sized tissue engineering constructs. Producing tissue engineering constructs at human scale has proven difficult, and this strategy presents a broadly applicable tool to enhance a cells ability to produce tissue at these scales, as we saw an ∼8-88 fold increase in tissue deposition and significantly improved biomechanics in large tissue engineered intervertebral disc compared to traditional growth factor differentiation methods. Additionally, this work begins to elucidate the biology of this novel zinc finger protein, which appears to be critical in regulating cell function and activity.

Indexed as

Intervertebral DiscStem CellsTissue EngineeringBiomechanical PhenomenaCartilageClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsHumansBLSTCell and tissue engineeringCRISPR-activationDegenerative disc diseaseIntervertebral disc

Identifiers

PMID39521313
PMCPMC13041521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.